Platelet-activating factor (PAF) in internal jugular venous blood of migraine without aura patients assessed during migraine attacks.
The aim of the study was to verify the production of PAF and the activity of PAF acetyl-hydrolase (PAF-AH), the enzyme involved in the catabolism of this phospholipid mediator, in migraine attacks. Their levels were determined during migraine crises in serial samples of internal jugular venous blood taken from five migraine patients without aura, who were admitted to the hospital during the crises. Internal jugular venous blood samples were taken immediately after catheter insertion at 1, 2, and 4 h after attack onset, and within 2 h from its cessation. PAF was purified by high-performance liquid chromatography (HPLC) and determined by radioimmunoassay method. The enzymatic activity of PAF-AH was measured by reverse-phase HPLC, based on the derivatization with 7-diethylaminocoumarin-3-carbonylazide. In the internal jugular venous blood of migraine patients without aura (MO), an increase was observed in PAF levels, which was already evident at the time of catheter insertion (885.6 +/- 82.8) and at the first hour (868.4 +/- 65.24) (ANOVA: P < 0.0001). PAF levels remained elevated through the second (746.8 +/- 82.95), fourth (700.6 +/- 34.93) and sixth hours (644.4 +/- 42.85), and then decreased at the end of the attack, reaching levels significantly lower than those measured at the time of catheter insertion (565.5 +/- 38.34). The activity of PAF-AH showed an opposite trend with higher values at the first hour and significantly lower values at the second and fourth hours from the beginning of the migraine attack (ANOVA: P < 0.02). The increased production of PAF may account for persistent platelet activation during migraine crises, even in the presence of an increased production of nitric oxide (NO) end-products which, on the other hand, should instead intervene in counteracting and limiting platelet activation. Potential sources of PAF production are the endothelial cells from cerebral vessels, stimulated by trigeminal neuropeptides, platelets themselves, and mast cells, as suggested by the neurogenic inflammation model.
Sarchielli
P
P
Department of Neuroscience, Institute of Clinical and Applied Biochemistry, University of Perugia, Perugia, Italy. neuro.pg@tiscalinet.it
Alberti
A
A
Coppola
F
F
Baldi
A
A
Gallai
B
B
Floridi
Al
A
Floridi
Ar
A
Capocchi
G
G
Gallai
V
V
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000097:blood*; D000328:Adult; D002851:Chromatography, High Pressure Liquid; D004789:Enzyme Activation; D005260:Female; D006801:Humans; D007601:Jugular Veins / Q000378:metabolism; D008297:Male; D020326:Migraine without Aura / Q000097:blood*; D010972:Platelet Activating Factor / Q000032:analysis*; D011863:Radioimmunoassay; D013997:Time Factors
D010972:Platelet Activating Factor; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase